Suzanne Jan de Beur, MD
Endocrinology, Diabetes & Metabolism · Charlottesville, VANPI 1073560801
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $68,421 of the $94,268 with a category attached, or 72.6%. Kyowa Kirin, Inc. accounts for 63.3% of it on its own, with 7 other manufacturers making up the rest. 2025 is the largest year on record at $32,927, 4.6 times the $7,157 reported in 2019. Among endocrinology, diabetes & metabolism clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 81 payments — averaging $1163.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Kyowa Kirin, Inc.$60K
- Kyowa Kirin Services Ltd$13K
- Ultragenyx Pharmaceutical Inc.$11K
- Ascendis Pharma Endocrinology Inc$4K
- Amgen$3K
- Regeneron$2K
- plus $2K from 2 others
Across 86 payments — averaging $16,541 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ultragenyx Pharmaceutical Inc.$1.4M
- Shire North American Group Inc$7K
What the payments were for
- Consulting fees$68,42173%
- Speaking & faculty fees$17,53619%
- Travel & lodging$6,3147%
- Food & beverage$1,9982%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Kyowa Kirin, Inc. | 62 | $59,669 |
| Kyowa Kirin Services Ltd | 3 | $13,326 |
| Ultragenyx Pharmaceutical Inc. | 7 | $10,506 |
| Ascendis Pharma Endocrinology Inc | 2 | $3,640 |
| Amgen | 2 | $2,655 |
| Regeneron | 2 | $2,324 |
| Novo Nordisk Health Care AG | 2 | $2,093 |
| Pfizer | 1 | $55 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$94,268 in reported general payments places this provider in the 95th percentile of 223 endocrinology, diabetes & metabolism providers in Virginia.
See all endocrinology, diabetes & metabolism providers in Virginia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Teriparatide | 13 | $76,169 |
| SynthroidLevothyroxine Sodium | 13 | $1,138 |
| Raloxifene Hcl | 20 | $568 |
| Alendronate Sodium | 55 | $379 |
| Levothyroxine Sodium | 17 | $292 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in Charlottesville
- Mary VanceCharlottesville$10K
- Kara HawkinsCharlottesville$9K
- Raghavendra MirmiraCharlottesville$6K
- Michael SantulliCharlottesville$5K
- Helmy SiragyCharlottesville$5K
- Erica GiraldiCharlottesville$4K
- Farhad ZangenehSterling$1.2M
- James MulindaRoanoke$788K
- Jeffrey SicatGlen Allen$657K
- Dewey BaileyRoanoke$645K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.